Which has stronger earnings and valuation, HSIC or LH?

Labcorp has higher revenue and earnings than Henry Schein. Labcorp is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Henry Schein $13.18B 0.73 $398M $3.31 25.66 Labcorp $13.95B 1.60 $876.50M $11.29 24.10

Is HSIC or LH more profitable?

Labcorp has a net margin of 6.66% compared to Henry Schein's net margin of 2.95%. Labcorp's return on equity of 16.29% beat Henry Schein's return on equity. Company Net Margins Return on Equity Return on Assets Henry Schein 2.95% 15.44% 5.53% Labcorp 6.66% 16.29% 7.62%

Does the media favor HSIC or LH?

In the previous week, Labcorp had 5 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for Labcorp and 6 mentions for Henry Schein. Henry Schein's average media sentiment score of 1.23 beat Labcorp's score of 0.99 indicating that Henry Schein is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MEDP or LH?

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.95 $451.12M $15.91 33.13 Labcorp $13.95B 1.60 $876.50M $11.29 24.10

Is MEDP or LH more profitable?

Medpace has a net margin of 17.19% compared to Labcorp's net margin of 6.66%. Medpace's return on equity of 120.89% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% Labcorp 6.66% 16.29% 7.62%

Does the media prefer MEDP or LH?

In the previous week, Labcorp had 8 more articles in the media than Medpace. MarketBeat recorded 11 mentions for Labcorp and 3 mentions for Medpace. Medpace's average media sentiment score of 1.22 beat Labcorp's score of 0.99 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LH or AMN?

In the previous week, Labcorp had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 11 mentions for Labcorp and 10 mentions for AMN Healthcare Services. Labcorp's average media sentiment score of 0.99 beat AMN Healthcare Services' score of 0.29 indicating that Labcorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, LH or BIO?

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $13.95B 1.60 $876.50M $11.29 24.10 Bio-Rad Laboratories $2.58B 3.11 $759.90M $6.07 49.45

Does the media favor LH or BIO?

In the previous week, Labcorp had 8 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 11 mentions for Labcorp and 3 mentions for Bio-Rad Laboratories. Labcorp's average media sentiment score of 0.99 beat Bio-Rad Laboratories' score of 0.82 indicating that Labcorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CAH or LH?

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardinal Health $222.58B 0.25 $1.56B $6.54 36.38 Labcorp $13.95B 1.60 $876.50M $11.29 24.10

Does the media prefer CAH or LH?

In the previous week, Labcorp had 9 more articles in the media than Cardinal Health. MarketBeat recorded 11 mentions for Labcorp and 2 mentions for Cardinal Health. Cardinal Health's average media sentiment score of 1.07 beat Labcorp's score of 0.99 indicating that Cardinal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Labcorp (LH) Competitors

$272.09 +5.75 (+2.16%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$271.48 -0.61 (-0.22%)

As of 06/26/2026 07:31 PM Eastern

Compare

LH vs. HSIC, MEDP, AMN, BIO, and CAH

Should you buy Labcorp stock or one of its competitors? MarketBeat compares Labcorp with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Labcorp include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Bio-Rad Laboratories (BIO), and Cardinal Health (CAH). These companies are all part of the "medical" sector.

How does Labcorp compare to Henry Schein?

Henry Schein (NASDAQ:HSIC) and Labcorp (NYSE:LH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Labcorp has a net margin of 6.66% compared to Henry Schein's net margin of 2.95%. Labcorp's return on equity of 16.29% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.95%	15.44%	5.53%
Labcorp	6.66%	16.29%	7.62%

Henry Schein has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Labcorp has higher revenue and earnings than Henry Schein. Labcorp is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18B	0.73	$398M	$3.31	25.66
Labcorp	$13.95B	1.60	$876.50M	$11.29	24.10

Henry Schein currently has a consensus price target of $87.85, indicating a potential upside of 3.41%. Labcorp has a consensus price target of $308.00, indicating a potential upside of 13.20%. Given Labcorp's stronger consensus rating and higher possible upside, analysts clearly believe Labcorp is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 0.9% of Henry Schein shares are held by insiders. Comparatively, 0.8% of Labcorp shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Labcorp had 5 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for Labcorp and 6 mentions for Henry Schein. Henry Schein's average media sentiment score of 1.23 beat Labcorp's score of 0.99 indicating that Henry Schein is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Labcorp beats Henry Schein on 12 of the 16 factors compared between the two stocks.

How does Labcorp compare to Medpace?

Medpace (NASDAQ:MEDP) and Labcorp (NYSE:LH) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Medpace has a net margin of 17.19% compared to Labcorp's net margin of 6.66%. Medpace's return on equity of 120.89% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Labcorp	6.66%	16.29%	7.62%

Medpace currently has a consensus target price of $467.08, suggesting a potential downside of 11.38%. Labcorp has a consensus target price of $308.00, suggesting a potential upside of 13.20%. Given Labcorp's stronger consensus rating and higher possible upside, analysts plainly believe Labcorp is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.95	$451.12M	$15.91	33.13
Labcorp	$13.95B	1.60	$876.50M	$11.29	24.10

In the previous week, Labcorp had 8 more articles in the media than Medpace. MarketBeat recorded 11 mentions for Labcorp and 3 mentions for Medpace. Medpace's average media sentiment score of 1.22 beat Labcorp's score of 0.99 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Labcorp has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Summary

Medpace beats Labcorp on 9 of the 16 factors compared between the two stocks.

How does Labcorp compare to AMN Healthcare Services?

Labcorp (NYSE:LH) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, Labcorp had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 11 mentions for Labcorp and 10 mentions for AMN Healthcare Services. Labcorp's average media sentiment score of 0.99 beat AMN Healthcare Services' score of 0.29 indicating that Labcorp is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Labcorp currently has a consensus target price of $308.00, suggesting a potential upside of 13.20%. AMN Healthcare Services has a consensus target price of $27.00, suggesting a potential downside of 17.19%. Given Labcorp's stronger consensus rating and higher probable upside, research analysts clearly believe Labcorp is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Labcorp has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.60	$876.50M	$11.29	24.10
AMN Healthcare Services	$2.73B	0.46	-$95.70M	-$0.87	N/A

95.9% of Labcorp shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.8% of Labcorp shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Labcorp has a net margin of 6.66% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.66%	16.29%	7.62%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Labcorp has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Summary

Labcorp beats AMN Healthcare Services on 13 of the 16 factors compared between the two stocks.

How does Labcorp compare to Bio-Rad Laboratories?

Labcorp (NYSE:LH) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Labcorp currently has a consensus price target of $308.00, suggesting a potential upside of 13.20%. Bio-Rad Laboratories has a consensus price target of $303.33, suggesting a potential upside of 1.06%. Given Labcorp's stronger consensus rating and higher probable upside, equities research analysts plainly believe Labcorp is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Labcorp had 8 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 11 mentions for Labcorp and 3 mentions for Bio-Rad Laboratories. Labcorp's average media sentiment score of 0.99 beat Bio-Rad Laboratories' score of 0.82 indicating that Labcorp is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.9% of Labcorp shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 0.8% of Labcorp shares are held by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Labcorp has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Labcorp has a net margin of 6.66% compared to Bio-Rad Laboratories' net margin of 6.52%. Labcorp's return on equity of 16.29% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.66%	16.29%	7.62%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.60	$876.50M	$11.29	24.10
Bio-Rad Laboratories	$2.58B	3.11	$759.90M	$6.07	49.45

Summary

Labcorp beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Labcorp compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and Labcorp (NYSE:LH) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Labcorp pays out 25.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years. Labcorp is clearly the better dividend stock, given its higher yield and lower payout ratio.

Cardinal Health currently has a consensus target price of $246.93, suggesting a potential upside of 3.80%. Labcorp has a consensus target price of $308.00, suggesting a potential upside of 13.20%. Given Labcorp's higher probable upside, analysts plainly believe Labcorp is more favorable than Cardinal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Labcorp had 9 more articles in the media than Cardinal Health. MarketBeat recorded 11 mentions for Labcorp and 2 mentions for Cardinal Health. Cardinal Health's average media sentiment score of 1.07 beat Labcorp's score of 0.99 indicating that Cardinal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardinal Health has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 0.1% of Cardinal Health shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Labcorp has a net margin of 6.66% compared to Cardinal Health's net margin of 0.62%. Labcorp's return on equity of 16.29% beat Cardinal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.62%	-92.61%	4.46%
Labcorp	6.66%	16.29%	7.62%

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$222.58B	0.25	$1.56B	$6.54	36.38
Labcorp	$13.95B	1.60	$876.50M	$11.29	24.10

Summary

Labcorp beats Cardinal Health on 12 of the 19 factors compared between the two stocks.

Get Labcorp News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LH vs. The Competition

Export

Metric	Labcorp	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$22.26B	$9.40B	$7.04B	$23.31B
Dividend Yield	1.06%	1.66%	2.66%	4.07%
P/E Ratio	24.10	25.95	26.13	31.64
Price / Sales	1.60	16.91	600.49	21.37
Price / Cash	10.93	112.91	47.95	24.80
Price / Book	2.62	5.99	10.78	4.74
Net Income	$876.50M	$179.69M	$3.58B	$1.07B
7 Day Performance	6.30%	4.28%	2.22%	0.99%
1 Month Performance	3.47%	3.89%	-0.09%	0.46%
1 Year Performance	4.53%	15.52%	34.39%	25.30%

Labcorp Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LH Labcorp	4.413 of 5 stars	$272.09 +2.2%	$308.00 +13.2%	+4.5%	$22.26B	$13.95B	24.10	71,000	News Coverage Positive News
HSIC Henry Schein	3.8551 of 5 stars	$78.67 -1.6%	$87.85 +11.7%	+15.9%	$9.10B	$13.18B	23.77	25,000
MEDP Medpace	2.2161 of 5 stars	$455.66 -1.0%	$467.08 +2.5%	+69.6%	$13.14B	$2.53B	28.64	6,200	Positive News
AMN AMN Healthcare Services	1.692 of 5 stars	$30.40 -1.9%	$25.29 -16.8%	+56.1%	$1.20B	$2.73B	N/A	2,664	News Coverage Analyst Forecast
BIO Bio-Rad Laboratories	0.9889 of 5 stars	$280.92 -0.5%	$303.33 +8.0%	+23.0%	$7.56B	$2.58B	46.28	7,450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:LH) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Labcorp (LH) Competitors

LH vs. HSIC, MEDP, AMN, BIO, and CAH

How does Labcorp compare to Henry Schein?

Summary

How does Labcorp compare to Medpace?

Summary

How does Labcorp compare to AMN Healthcare Services?

Summary

How does Labcorp compare to Bio-Rad Laboratories?

Summary

How does Labcorp compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LH vs. The Competition

Labcorp Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Labcorp (LH) Competitors

LH vs. HSIC, MEDP, AMN, BIO, and CAH

How does Labcorp compare to Henry Schein?

Is HSIC or LH more profitable?

Which has more volatility & risk, HSIC or LH?

Which has stronger earnings and valuation, HSIC or LH?

Do analysts rate HSIC or LH?

Do institutionals and insiders believe in HSIC or LH?

Does the media favor HSIC or LH?

Summary

How does Labcorp compare to Medpace?

Is MEDP or LH more profitable?

Do analysts rate MEDP or LH?

Do institutionals & insiders believe in MEDP or LH?

Which has stronger earnings and valuation, MEDP or LH?

Does the media prefer MEDP or LH?

Which has more volatility and risk, MEDP or LH?

Summary

How does Labcorp compare to AMN Healthcare Services?

Does the media refer more to LH or AMN?

Do analysts recommend LH or AMN?

Which has stronger valuation & earnings, LH or AMN?

Do institutionals and insiders hold more shares of LH or AMN?

Is LH or AMN more profitable?

Which has more risk and volatility, LH or AMN?

Summary

How does Labcorp compare to Bio-Rad Laboratories?

Do analysts prefer LH or BIO?

Does the media favor LH or BIO?

Do institutionals & insiders hold more shares of LH or BIO?

Which has more risk & volatility, LH or BIO?

Is LH or BIO more profitable?

Which has preferable valuation & earnings, LH or BIO?

Summary

How does Labcorp compare to Cardinal Health?

Is CAH or LH a better dividend stock?

Do analysts rate CAH or LH?

Does the media prefer CAH or LH?

Which has more risk & volatility, CAH or LH?

Do institutionals and insiders believe in CAH or LH?

Is CAH or LH more profitable?

Which has better earnings & valuation, CAH or LH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LH vs. The Competition

Labcorp Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools